BridgeBio Pharma, Inc. (BBIO, Financial) has secured marketing authorization from the UK’s Medicines and Healthcare products Regulatory Agency for its drug acoramidis, marketed as Beyonttra. This approval is specifically for adult patients suffering from transthyretin amyloidosis-related cardiomyopathy (ATTR-CM), whether of the wild-type or variant form.
Acoramidis is an innovative, selective small molecule designed to stabilize the transthyretin protein, administered orally to patients. ATTR-CM is a progressive and life-threatening condition that leads to heart failure due to its restrictive impact on heart function.
For the commercial rollout of Beyonttra in the UK, BridgeBio has partnered with Bayer, which will oversee all marketing and distribution efforts. This collaboration aims to address the unmet medical needs of patients living with this challenging cardiac disorder.
